Michael A Johnson

Dr. Michael A Johnson

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2004 in Analytical Chemistry
Verified
Journal Article
Closed access
MHMichael L. A. V. Heien
Michael L. A. V. Heien
MJMichael A Johnson
Michael A Johnson
RWR. Mark Wightman
R. Mark Wightman

1 September 2001 in Nature
Verified
Journal Article
Closed access
PDF file
ALAndrew J. Lipton
Andrew J. Lipton
MJMichael A Johnson
Michael A Johnson
TMTimothy Macdonald
Timothy Macdonald
MLMichael W. Lieberman
Michael W. Lieberman
DGDavid Gozal
David Gozal
BGBenjamin Gaston
Benjamin Gaston

18 June 2008 in Chemical Reviews
Verified
Journal Article
Closed access
GWGeorge S. Wilson
George S. Wilson
MJMichael A Johnson
Michael A Johnson

1 April 2002 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
ASAshley H. Snyder
Ashley H. Snyder
MMMarianne E. McPherson
Marianne E. McPherson
JHJohn F. Hunt
John F. Hunt
MJMichael A Johnson
Michael A Johnson
JSJonathan S. Stamler
Jonathan S. Stamler
BGBenjamin Gaston
Benjamin Gaston
S-Nitrosoglutathione (GSNO), a naturally occurring constituent of airway lining fluid, enhances ciliary motility, relaxes airway smooth muscle, inhibits airway epithelial amiloride-sensitive sodium transport, and prevents pathogen replication. Remarkably, airway levels of GSNO are low in patients with cystic fibrosis (CF). We hypothesized that replacement of airway GSNO would improve gas exchange in CF. In a double-blind, placebo controlled study, we administered 0.05 ml/kg of 10 mM GSNO or phosphate buffered saline by aerosol to patients with CF and followed oxygen saturation, spirometry, respiratory rate, blood pressure, heart rate, and expired nitric oxide (NO). Nine patients received GSNO and 11 placebo. GSNO inhalation was associated with a modest but sustained increase in oxygen saturation at all time points. Expired NO increased in the low ppb range with GSNO treatment, peaking at 5 minutes but remaining above baseline at 30 minutes. There were no adverse effects. We conclude that GSNO is well tolerated in patients with CF and improves oxygenation through a mechanism that may be independent of free NO. Further, GSNO breakdown increases expired NO. We suggest that therapy aimed at restoring endogenous GSNO levels in the CF airway may merit study.

29 March 2006 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
MJMichael A Johnson
Michael A Johnson
VRVignesh Rajan
Vignesh Rajan
CMCharles E. Miller
Charles E. Miller
RWR. Mark Wightman
R. Mark Wightman

6 February 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
CSChristopher M. Schonhoff
Christopher M. Schonhoff
MMMasaaki Matsuoka
Masaaki Matsuoka
HTHemachand Tummala
Hemachand Tummala
MJMichael A Johnson
Michael A Johnson
AEAlvaro G. Estevéz
Alvaro G. Estevéz
JMJoan B. Mannick
Joan B. Mannick
Recent data suggest that either excessive or deficient levels of protein S-nitrosylation may contribute to disease. Disruption of S -nitrosothiol (SNO) homeostasis may result not only from altered nitric oxide (NO) synthase activity but also from alterations in the activity of denitrosylases that remove NO groups. A subset of patients with familial amyotrophic lateral sclerosis (ALS) have mutations in superoxide dismutase 1 (SOD1) that increase the denitrosylase activity of SOD1. Here, we show that the increased denitrosylase activity of SOD1 mutants leads to an aberrant decrease in intracellular protein and peptide S-nitrosylation in cell and animal models of ALS. Deficient S-nitrosylation is particularly prominent in the mitochondria of cells expressing SOD1 mutants. Our results suggest that SNO depletion disrupts the function and/or subcellular localization of proteins that are regulated by S-nitrosylation such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and thereby contributes to ALS pathogenesis. Repletion of intracellular SNO levels with SNO donor compounds rescues cells from mutant SOD1-induced death. These results suggest that aberrant depletion of intracellular SNOs contributes to motor neuron death in ALS, and raises the possibility that deficient S-nitrosylation is a general mechanism of disease pathogenesis. SNO donor compounds may provide new therapeutic options for diseases such as ALS that are associated with deficient S-nitrosylation.